arrow
A

Axel Nierhaus

University of Hamburg
H指数:45
被引数:9,035

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CYP19A1 mediates severe SARS-CoV-2 disease outcome in males

CYP19A1介导男性严重SARS-CoV-2疾病转归

2023-09-017
OAAI
Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study
2022-07-0713
OAAI
Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial (vol 48, pg 311, 2022)
2022-03-182
OAAI
Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial
2022-03-0120
PRE
Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial

基于治疗药物监测的哌拉西林/他唑巴坦剂量优化对脓毒症相关器官功能障碍影响的随机对照试验

2022-02-01107
OAAI
Replication of SARS-CoV-2 in adipose tissue determines organ and systemic lipid metabolism in hamsters and humans
2022-01-0142
OAAI
Clinical Characteristics, Complications and Outcomes of Patients with Severe Acute Respiratory Distress Syndrome Related to COVID-19 or Influenza Requiring Extracorporeal Membrane Oxygenation-A Retrospective Cohort Study
2021-11-2111
OAAI
High estradiol and low testosterone levels are associated with critical illness in male but not in female COVID-19 patients: a retrospective cohort study
2021-09-1454
OAAI
Hepatic Vasculopathy and Regenerative Responses of the Liver in Fatal Cases of COVID-19
2021-08-0129
OAAI
Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020
2021-05-2416
OAAI